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Abstract: Wastewater was screened for the presence of functionally significant mutations in
SARS-CoV-2 associated with emerging variants of concern (VOC) by ddPCR, and results
accorded with sequencing of clinical samples from the same region. We propose that PCR-based
screening of wastewater can provide a powerful tool for rapid and inexpensive screening of large
population segments for VOC-associated mutations and can hone complementary sampling and
sequencing of direct (human) test material to track emerging VOC.
Several SARS-CoV-2 variants of concern have been identified that show elevated
transmissibility (Tegally et al. 2020, Tu et al. 2021, Volz et al. 2021, Galloway et al. 2021, Lauring
and Hodcraft 2021). The mechanisms driving this transmissibility are not fully understood, but
select VOC-associated mutations have been found to strengthen viral binding to host cell receptors
(Starr et al. 2020), inhibit antibody binding (Gupta et al. 2020) and increase viral replication within
human tissues (Plante et al. 2020). Research is actively underway to assess whether newly
emerging variants are linked to higher disease severity in infected humans and/or resistant to
vaccine-induced immunity (Lauring and Hodcroft 2021, de Cosio et al. 2021). Regardless,
characterizing the emergence and spread of VOC is crucial to pandemic mitigation because an
increase in transmissibility means an increase in cases, and a heightened potential for further
emergences of VOC. These effects may impact the success of vaccination programs designed to
achieve herd immunity and end the COVID-19 pandemic. Intercontinental exchanges of VOC,
and convergent evolution of VOC-associated mutations (Kemp et al. 2020, Gupta et al. 2021, Tu
et al. 2021, Washington et al. 2021), further suggest that new variants will emerge within many
communities before SARS-CoV-2 can be extirpated.
Investigators have recently deployed analyses of wastewater to overcome logistical and
budgetary constraints posed by standard phylodynamic surveys of circulating SARS-CoV-2
genotypes (i.e., sequencing of individual patient samples). This approach leverages the discovery
that SARS-CoV-2 infected hosts shed viral RNA in feces; this shedding also precedes symptom
onset in those who develop COVID-19. Sewage samples have been used since the early stages of
the ongoing pandemic to track prevalence trends and forecast impending cases (e.g., Bivens et al.
2020, Gonzalez et al. 2020, Peccia et al. 2020, Stadler et al. 2020). Furthermore, Jahn et al. (2021)
recently deployed next-generation sequencing (NGS) of wastewater samples to identify SARSCoV-2 VOCs in archival wastewater material, discovering that a highly transmissible emerging
lineage (B.1.1.7) was established in Switzerland prior to its discovery within a patient sample. This
work illustrates the broad utility of wastewater testing for VOC tracking, but NGS genomic
analyses are also costly, time consuming, sensitive to inhibition, and challenging to interpret. More
rapid and robust approaches to VOC screening of wastewater samples are urgently needed in order
to enhance these sequencing efforts and leverage limited resources.
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In the present study we utilize outsourced digital droplet PCR (ddPCR) analyses of
wastewater to ascertain the emergence of two VOC-associated mutations in the RNA encoding
SARS-CoV-2’s spike protein (N501Y and 69-70del) within raw wastewater samples from several
wastewater facilities in South Florida. This approach employs a rapid assessment protocol for the
identification of viral genotypes circulating in over a million residents, with ~24-hour turnaround
at extremely low cost. An additional advantage of this approach is that wastewater analyses
provide egalitarian indexes of focal communities, circumventing problematic biases in direct
testing (e.g., effects of an individual’s age, mobility, work status, Internet access, etc. on the
likelihood of undergoing a standard COVID-19 test).
We targeted two mutations, N501Y and 69-70del, for screening in influent wastewater
samples in January 2021. The first mutation, N501Y, appears to enhance SARS-CoV-2
transmission based on its rapid spread in SARS-CoV-2 lineages that emerged in parallel within
the UK (B.1.1.7/501Y.V1) and South Africa (B.1.351/501Y.V2). N501Y is also found in an
emerging variant first reported from Brazil (B.1.1.248/501Y.V3/P1) that was found in a Minnesota
patient who was sampled on January 9, 2021, following travel to Brazil. N501Y involves a single
replacement in the ACE2 binding motif that is predicted to increase the strength of binding
between spike and hACE2-expressing host cells (Starr et al. 2020). We also screened wastewater
samples for 69-70del, a 6bp deletion that occurs on several backgrounds including B.1.1.7. B.1.1.7
currently occurs at increasing frequencies across the United States (US). The first US case was
reported on December 29, 2020, and a case within central Florida was reported just two days later.
Washington et al. (2021) provided phylogenetic evidence that B.1.1.7 reached the US via multiple
introductions starting at least as early as November 2020. The 69-70del that is found in B.1.1.7 is
also found in other SARS-CoV-2 lineages, including two variants that show no indications of
elevated transmissibility in humans: the Danish ‘mink strain’ and B1.375, the latter of which has
been reported in a patchy distribution across the US via sequencing of patient swabs. Thus, of the
two mutations we screened by ddPCR, N501Y is of highest concern since it involves functional
changes expected to enhance hACE2 binding, whereas 69-70del is often, but not always, found in
rapidly spreading VOC including B.1.1.7 and 501Y.V2.
Figure 1. SARS-CoV-2 loci assayed by ddPCR in the present
study rendered by COV3D (Gowthaman et al. in press).
N501Y involves the spike protein’s receptor binding motif
and is reported to: a) increase the strength of spike binding
to human host cell receptors (hACE2) and b) inhibit the
binding of select neutralizing host antibodies. N501Y occurs
in multiple SARS-CoV-2 lineages within North America.
69-70del involves the deletion of two amino acids the spike
protein. Like N501Y, 69-70del has evolved in multiple
SARS-CoV-2 lineages including B.1.1.7 – a variant that
contains several additional derived mutations inclusive of
N501Y. The other color-filled mutation in the illustrations
above is D614G which is now found at high frequency
worldwide and associated with enhanced viral replication in
respiratory tissues (Plante et al. 2020, Hou et al. 2020).
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Table One: Recovery-adjusted concentrations of SARS-CoV-2 in wastewater measured using ddPCR targeting the
conserved (EUA) N1 locus and the proportion of droplets containing two focal mutations (N501Y and 69-70del) that
are associated with emerging SARS-CoV-2 variants.
Population
RecoveryBCoV
%N501Y
%69-70del
serviced
adjusted
Recovery (%)
(N residents)
SC2 (copies/L)
Source#1
631,000
946,673
5.88%
4.926
1.370
Source#2

338,000

2,187,749

7.17%

9.122

2.471

Source#3

226,000

1,148,302

4.95%

3.284

1.943

Source#4

131,000

2,190,138

7.35%

2.279

0.529

Total population surveyed =
1,326,000

Weighted average N501Y = 5.03%
Weighted average 69-70del = 1.43%
(weighting based on recovery-adjusted SC2 levels)

Wastewater-testing by ddPCR provided an inexpensive and rapid method of screening for
the presence of VOC-associated mutations in large populations totaling over a million residents.
Both mutations we screened for were identified at all four surveyed treatment locations (Table
One). This demonstrates the widespread presence of emerging SARS-CoV-2 genotypes within the
study region. The result was not surprising given that the US Center for Disease
Control announced confirmed cases of B.1.1.7 (which contains both focal mutations) in California,
central Florida, Colorado, Georgia, and New York on January 6, 2021, the same week our
wastewater samples were collected. Additionally, a convergently-evolved strain containing the
N501Y mutation was discovered in the US in December 2020 (Tu et al. 2020); infections involving
this lineage and/or undiscovered clade(s) may underlie our findings of N501Y and 69-70del in
regional wastewater.
At the present time, both N501Y and 69-70del are present at low frequency at each of the
sampled localities. This pattern is suggestive of a generally low prevalence of infections involving
VOCs upstream of the sampled sewage plants and comports with sequencing results from recent
human clinical specimens. Florida Bureau of Public Health Laboratories sequenced 220 SARSCoV-2-positive clinical samples from the same geographic region as the wastewater facilities from
March 2020 through January 2021 as part of routine surveillance of SARS-CoV-2. N501Y was
detected in one surveillance sample (0.45% frequency), and S69-70del was detected in five
surveillance samples (2.27% frequency), which includes one sample from the B.1.1.7 lineage with
both mutations. Five additional B.1.1.7 samples were detected from the same region during
targeted screening for VOC in January 2021. It is too soon to tell if these variants are increasing
over time in the study region; thus, continued monitoring and sequencing of both environmental
and human samples should be a key research priority. We also note that shedding rates may differ
between hosts who are infected with divergent SARS-CoV-2 genotypes. Until this has been
established, frequencies of VOC and/or specific mutations found in wastewater (e.g. via ddPCR
or sequencing) cannot provide precise estimates of the proportion of COVID-19 cases in a
community that involve a mutation or lineage of interest.
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Our wastewater analyses alone cannot determine which viral lineage(s) are present (and
contain the two mutations detected via ddPCR), though clearly they include lineages other than
B.1.1.7, given the unbalanced frequencies of N501Y and 69-70del in our samples. Identifying
specific clades in North American wastewater samples will require RNA sequencing approaches
(as in Jahn et al. 2021), and/or development of strain-specific ddPCR protocols. However, we have
shown here that ddPCR assays of VOC markers can play a crucial role in focusing this work pinpointing geographical regions or timepoints over which to prioritize SARS-CoV-2 sequencing.
Looking ahead, we expect that a two-step approach involving PCR screening to identify
sequencing targets at various scales, and subsequent genotyping of environmental or human
samples will provide a highly efficient approach to phylodynamic epidemiology. This could be
facilitated by nascent wastewater surveillance networks (e.g. those under development in the US
and EU), open source protocols to screen for VOC-associated mutations (e.g. Vogels et al. 2021)
and thriving research collaborations emerging worldwide, in parallel with VOC.
Methods: 24-hour flow-metered composite samples of primary influent wastewater were
collected under refrigeration using autosamplers. Samples were held at 4°C and processed via
extraction and ddPCR within ~72-hour windows by a commercial laboratory (GT Molecular,
Fort Collins Colorado). In brief, BCoV surrogate virus was added to each wastewater sample,
and RNA was then isolated from 40mL aliquots for amplification of CDC’s EUA N1 locus
target. Measured total SARS-CoV-2 concentrations (using the N1 locus) were then adjusted for
effects of each wastewater matrix using recovery fractions determined via ddPCR amplification
of the BCoV surrogate spike-in. Each sample was then subjected to ddPCR screening for the
frequencies of the two targeted (VOC-associated) mutations.
RNA from clinical specimens
Primary specimens were received at the Bureau of Public Health Laboratories, Florida Department
of Health and confirmed for the presence of SARS-CoV-2 RNA. RNA was purified by multiple
methods, including: Kingfisher combined with the Thermo Fisher MagMAX Viral/Pathogen II
(MVP II) Nucleic Acid Isolation kit (Applied Biosystems by Thermo Fisher Scientific, Waltham,
MA); Abbott m2000 System combined with the Abbott RealTime SARS-CoV-2 assay (Abbott,
Lake County, IL;, MagNA Pure 96 combined with the MagNA Pure 96 DNA and Viral NA Small
Volume Kit (Roche, Indianapolis, IN); MagNA Pure LC 2.0 combined with the MagNA Pure LC
Total Nucleic Acid Isolation Kit (Roche, Indianapolis, IN); and EZ1 Advanced combined with the
EZ1 DSP Virus Kit (Qiagen, Germantown, MD), QIAamp DSP Viral RNA Mini Kit (Qiagen,
Germantown, MD).
cDNA and amplicon generation
cDNA was synthesized from RNA with the following reaction: 10 µL template RNA, 6 µL
nuclease-free water, 4 µL SuperScript IV VILO Master Mix (Thermo Fisher Scientific, Waltham,
MA). cDNA synthesis reactions were incubated at: 25°C for 10 minutes, followed by 50°C for 10
minutes, and 85°C for 5 minutes. cDNA was amplified using each of the two ARTIC v3 primer
pools (https://artic.network/ncov-2019) (Integrated DNA Technologies, Inc, Coralville, IA) which
tile the SARS-CoV-2 genome. That reaction contained: 12.5 µL Q5 2x Master Mix (New England
Biolabs, Ipswich, MA), 1 µL Primer pool (#1 or #2) (20 µM), 9 µL Nuclease-free water, and 2.5
µL cDNA. The amplicon reactions were incubated at: 98°C for 30 seconds, followed by 95°C for
15 seconds, and 64°C for 5 minutes (the last two steps were repeated a total of 35 times). Amplicon
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pools 1 and 2 were then combined, cleaned up with 1:1 Axygen™ AxyPrep Mag™ PCR Cleanup beads (Axygen, Union City, CA), and quantified by Qubit Fluorometer and Broad Range DNA
assay (Thermo Fisher Scientific, Waltham, MA).
Library generation and sequencing
Libraries were prepared from the amplicons using Illumina’s Nextera XT library prep kit
(Illumina, San Diego, CA) and quantified by Qubit Fluorometer and Broad Range DNA assay and
TapeStation capillary electrophoresis (Agilent, Santa Clara, CA). Equimolar amounts of each
library were pooled and concentrated to 20 µL using 0.7x Axygen™ AxyPrep Mag™ PCR Cleanup beads. The final pooled sample was quantified using a Qubit Fluorometer and High Sensitivity
DNA assay. To confirm the expected library size, pooled libraries were run on an Agilent
TapeStation. Libraries were sequenced on either an Illumina MiSeq or NextSeq 550 Dx. For the
MiSeq: The sample pools were diluted to 2 nM based on the Qubit measurements and Agilent
sizing information, and 10 µL of the 2 nM pool was denatured with 10 µL of 0.2 N NaOH.
Amplicon libraries were diluted to 8 pM in Illumina’s HT1 buffer, spiked with 5% PhiX, and
sequenced using a MiSeq 600 cycle v3 kit. For the NextSeq 550Dx: The sample pools were diluted
to 4 nM based on the Qubit measurements and Agilent sizing information, and 5 µL of the 4 nM
pool was denatured with 5 µL of 0.2 N NaOH. Amplicon libraries were diluted to 1.5 pM in
Illumina’s HT1 buffer, spiked with 1% PhiX, and sequenced using a NextSeq 500/550 Mid Output
Kit v2.5 (300 cycle).
SARS-CoV-2 genome assembly and variant detection
SARS-CoV-2 consensus assemblies were generated using a custom pipeline, FLAQ-SC2. Quality
metrics
were
generated
for
raw
sequence
reads
using
fastqc
v0.11.9
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and raw fastqs were quality filtered
and trimmed (SLIDINGWINDOW:4:30 MINLEN:75 TRAILING:20) using trimmomatic v0.39
(Bolger, et al. 2014). Sequence adapter and Phix contamination were removed using bbduk
(BBMap v38.79) (https://sourceforge.net/projects/bbmap/). Cleaned reads were mapped to SARSCoV-2 reference NC_045512.2 using bwa mem v0.7.17-r1188.(Li, H. 2013). PCR duplicates were
marked and removed using samtools v1.9.(Li, et al. 2009)). ARTIC primer sequences
(https://github.com/artic-network/artic-ncov2019/tree/master/primer_schemes/nCoV-2019/V3)
were trimmed from bam files using ivar trim v1.2.2 (Grubaugh, et al. 2019). Variants were called
using samtools mpileup v1.9 (Li, et al. 2009) and ivar variant v1.2.2 (Grubaugh, et al. 2019), and
consensus assemblies were generated using samtools mpileup v1.9 (Li, et al. 2009) and ivar
consensus v1.2.2 (Grubaugh, et al. 2019). Only variants as the major allele were included in the
final consensus assembly, and bases <10x were incorporated as N. Read mapping metrics were
generated using samtools coverage v1.10 (Li, et al. 2009). Only samples with ≥80% genome
coverage at ≥100x mean read depth were included in this study. B.1.1.7 lineages were determined
using Pangolin v2.1.8 (https://github.com/cov-lineages/pangolin).
SARS-CoV-2 consensus assemblies for clinical samples with N501Y and/or S69-70del mutations
are available on NCBI Genbank (MW452527-28, MW460886, MW494396-97, MW494398-99,
MW545525, MW560187-88) and GISAID (EPI_ISL_790567-68, EPI_ISL_802724,
EPI_ISL_852858-59,
EPI_ISL_852860-61,
EPI_ISL_906918,
EPI_ISL_918493,
EPI_ISL_918495).
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